Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | NMT1 | P30419 | 6/20 | 0.47 |
| ▸ | NMT2 | O60551 | 5/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 3/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16589734 | 0.88 | SIRT6 (0.49) | SIRT6SIRT1GRIA1NMT1NMT2 | |
| SCHEMBL16589746 | 0.85 | GRIA1 (0.45) | SIRT6SIRT1GRIA1NMT1NMT2 | |
| SCHEMBL16589745 | 0.84 | GRIA1 (0.43) | SIRT6SIRT1GRIA1NMT1NMT2 | |
| SCHEMBL16589748 | 0.84 | CCKBR (0.45) | SIRT6SIRT1GRIA1 | |
| SCHEMBL16589738 | 0.83 | GRIA1 (0.46) | SIRT6SIRT1GRIA1NMT1NMT2 | |
| SCHEMBL16589742 | 0.82 | CTSS (0.46) | SIRT6SIRT1GRIA1CA1CA2 | |
| SCHEMBL16589725 | 0.81 | GRIA1 (0.45) | SIRT6SIRT1GRIA1MMP1MMP3 | |
| SCHEMBL24824249 | 0.81 | HPGDS (0.42) | SIRT6SIRT1GRIA1CA1TLR2 | |
| SCHEMBL19647271 | 0.81 | SIRT6 (0.42) | SIRT6SIRT1GRIA1MMP1MMP3 | |
| SCHEMBL13049083 | 0.81 | FOLH1 (0.57) | MMP9CA1CA2CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ABCB1, CYP2D6, LDHA | SIRT6 1290/4885SIRT1 789/4885GRIA1 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.